Tag Archives: Intercept Pharmaceuticals

Ocaliva Side Effects Linked to Severe Liver Injuries in Some Cirrhosis Patients: FDA Warning

May 27, 2021 By: Irvin Jackson

The FDA has added a new warning to the liver drug Ocaliva, barring its use in patients with primary biliary cholangitis and advanced cirrhosis of the liver, due to the…
Ocaliva Dosing Problems Lead To FDA Black Box Warning

February 02, 2018 By: Irvin Jackson

The FDA is adding a new black box label warning to labels of Ocaliva, following reports of at least 19 deaths linked to incorrect dosing and severe liver injury.
Ocaliva Dosing Problems May Increase Liver Injury Risks, FDA Warns

September 22, 2017 By: Austin Kirk

The FDA is warning that the liver disease drug Ocaliva has been linked to cases of severe liver injury and death when inappropriate doses have been prescribed.

Lawsuit Against Uber Alleges Rideshare Service Fails to Protect Customers From Sexual Assaults (Posted 4 days ago)

Eight women have filed Uber sexual assault lawsuits, claiming the rideshare service failed to protect them from predatory drivers due to its lack of safety measures.

Families Say Camp Lejeune Settlement Fails to Address Countless Miscarriages, Birth Defects Caused By Water Contamination (Posted 5 days ago)

A new report highlights how many women and families feel left out of Camp Lejeune settlement negotiations after suffering repeated miscarriages they say were caused by miscarriages on the North Carolina military base.

Bard Infuse-A-Port Lawsuit Filed After Pulmonary Embolism, Catheter Fragments Found in Heart (Posted 6 days ago)

A Bard Infuse-A-Port lawsuit claims a piece of a failed port catheter broke off, causing a woman to suffer a pulmonary embolism which has resulted in fragments of the device remaining in her heart.

Tag Archives: Intercept Pharmaceuticals

Ocaliva Side Effects Linked to Severe Liver Injuries in Some Cirrhosis Patients: FDA Warning

Ocaliva Dosing Problems Lead To FDA Black Box Warning

Ocaliva Dosing Problems May Increase Liver Injury Risks, FDA Warns

More Top Stories

Review A Case